Literature DB >> 27041926

The update of prostatic ductal adenocarcinoma.

Tantan Liu1, Yingmei Wang1, Ru Zhou1, Haiyang Li1, Hong Cheng1, Jing Zhang1.   

Abstract

Since initially described in 1967, prostatic ductal adenocarcinoma (PDA) has engendered a series of controversies on its origin, histological features, and biological behavior. Owing to the improvement of molecular biological technique, there are some updated findings on the characteristics of PDA. In the current review, we will mainly analyze its origin, clinical manifestations, morphological features, differential diagnosis, immunophenotype and molecular genetics, with the purpose of enhancing recognition of this tumor and making a correct diagnosis and treatment choice.

Entities:  

Keywords:  Prostatic cancer; clinicopathology; differential diagnosis; ductal adenocarcinoma

Year:  2016        PMID: 27041926      PMCID: PMC4779765          DOI: 10.3978/j.issn.1000-9604.2016.02.02

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  41 in total

1.  Prostatic adenocarcinoma of ductal origin.

Authors:  L F Greene; G M Farrow; J M Ravits; F M Tomera
Journal:  J Urol       Date:  1979-03       Impact factor: 7.450

2.  Ductal adenocarcinoma of the prostate.

Authors:  Johann D Hertel; Peter A Humphrey
Journal:  J Urol       Date:  2011-05-20       Impact factor: 7.450

3.  Endometrial carcinoma of proxtatic utricle (uterus masculinus).

Authors:  M M Melicow; M R Pachter
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

Review 4.  Prostatic ductal adenocarcinoma: a mini review.

Authors:  Jonathan I Epstein
Journal:  Med Princ Pract       Date:  2009-12-09       Impact factor: 1.927

5.  Periurethral prostatic duct carcinoma: clinical features and treatment results.

Authors:  G Kopelson; L Harisiadis; N A Romas; R J Veenema; M Tannenbaum
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

6.  Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists.

Authors:  Amanda H Seipel; Brett Delahunt; Hemamali Samaratunga; Mahul Amin; Joel Barton; Daniel M Berney; Athanase Billis; Liang Cheng; Eva Comperat; Andrew Evans; Samson W Fine; David Grignon; Peter A Humphrey; Cristina Magi-Galluzzi; Rodolfo Montironi; Isabell Sesterhenn; John R Srigley; Kiril Trpkov; Theo van der Kwast; Murali Varma; Ming Zhou; Amar Ahmad; Sue Moss; Lars Egevad
Journal:  Histopathology       Date:  2014-04-03       Impact factor: 5.087

7.  Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.

Authors:  Souzan Sanati; Mark A Watson; Andrea L Salavaggione; Peter A Humphrey
Journal:  Mod Pathol       Date:  2009-07-24       Impact factor: 7.842

8.  Prostatic duct carcinoma with combined prostatic duct adenocarcinoma and urothelial carcinoma features: report of a case.

Authors:  D Pacchioni; G Casetta; M Piovano; F Fraire; M Volante; A Sapino; A Tizzani; G Bussolati
Journal:  Int J Surg Pathol       Date:  2004-07       Impact factor: 1.271

9.  Immunohistochemical verification of ductal differentiation in prostate cancer.

Authors:  Miklós Tarján; Anna Lenngren; Dan Hellberg; Tibor Tot
Journal:  APMIS       Date:  2012-01-12       Impact factor: 3.205

10.  An incidentally diagnosed prostatic ductal adenocarcinoma.

Authors:  Paweł Stajno; Tomasz Kalinowski; Marcin Ligaj; Tomasz Demkow
Journal:  Cent European J Urol       Date:  2013-08-13
View more
  3 in total

Review 1.  Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Authors:  Nithesh Ranasinha; Altan Omer; Yiannis Philippou; Eli Harriss; Lucy Davies; Ken Chow; Paolo M Chetta; Andrew Erickson; Timothy Rajakumar; Ian G Mills; Richard J Bryant; Freddie C Hamdy; Declan G Murphy; Massimo Loda; Christopher M Hovens; Niall M Corcoran; Clare Verrill; Alastair D Lamb
Journal:  BJUI Compass       Date:  2021-01-05

Review 2.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

3.  Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1+ prostate luminal cells.

Authors:  Oh-Joon Kwon; Li Zhang; Deyong Jia; Li Xin
Journal:  Oncogene       Date:  2020-10-27       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.